Transfer of phosphatidylcholine facilitated by a component of human plasma

Rethinking reverse cholesterol transport and dysfunctional high-density lipoproteins

Human plasma high-density lipoprotein cholesterol concentrations are a negative risk factor for atherosclerosis-linked cardiovascular disease. Pharmacological attempts to reduce atherosclerotic cardiovascular disease by increasing plasma high-density lipoprotein cholesterol have been disappointing so that recent research has shifted from HDL quantity to HDL quality, that is, functional vs dysfunctional HDL. HDL has varying degrees of dysfunction reflected in impaired reverse cholesterol transport (RCT). In the context of atheroprotection, RCT occurs by 2 mechanisms: one is the well-known trans-hepatic pathway comprising macrophage free cholesterol (FC) efflux, which produces early forms of FC-rich nascent HDL (nHDL). Lecithin:cholesterol acyltransferase converts HDL-FC to HDL-cholesteryl ester while converting nHDL from a disc to a mature spherical HDL, which transfers its cholesteryl ester to the hepatic HDL receptor, scavenger receptor B1 for uptake, conversion to bile salts, or transfer to the intestine for excretion. Although widely cited, current evidence suggests that this is a minor pathway and that most HDL-FC and nHDL-FC rapidly transfer directly to the liver independent of lecithin:cholesterol acyltransferase activity. A small fraction of plasma HDL-FC enters the trans-intestinal efflux pathway comprising direct FC transfer to the intestine. SR-B1^-/- mice, which have impaired trans-hepatic FC transport, are characterized by high plasma levels of a dysfunctional FC-rich HDL that increases plasma FC bioavailability in a way that produces whole-body hypercholesterolemia and multiple pathologies. The design of future therapeutic strategies to improve RCT will have to be formulated in the context of these dual RCT mechanisms and the role of FC bioavailability.

ABCA1-Derived Nascent High-Density Lipoprotein-Apolipoprotein AI and Lipids Metabolically Segregate

OBJECTIVE

Reverse cholesterol transport comprises cholesterol efflux from ABCA1-expressing macrophages to apolipoprotein (apo) AI, giving nascent high-density lipoprotein (nHDL), esterification of nHDL-free cholesterol (FC), selective hepatic extraction of HDL lipids, and hepatic conversion of HDL cholesterol to bile salts, which are excreted. We tested this model by identifying the fates of nHDL-[³H]FC, [¹⁴C] phospholipid (PL), and [¹²⁵I]apo AI in serum in vitro and in vivo.

APPROACH AND RESULTS

During in vitro incubation of human serum, nHDL-[³H]FC and [¹⁴C]PL rapidly transfer to HDL and low-density lipoproteins (t_1/2=2-7 minutes), whereas nHDL-[¹²⁵I]apo AI transfers solely to HDL (t_1/2<10 minutes) and to the lipid-free form (t_1/2>480 minutes). After injection into mice, nHDL-[³H]FC and [¹⁴C]PL rapidly transfer to liver (t_1/2=≈2-3 minutes), whereas apo AI clears with t_1/2=≈460 minutes. The plasma nHDL-[³H]FC esterification rate is slow (0.46%/h) compared with hepatic uptake. PL transfer protein enhances nHDL-[¹⁴C]PL but not nHDL-[³H]FC transfer to cultured Huh7 hepatocytes.

CONCLUSIONS

nHDL-FC, PL, and apo AI enter different pathways in vivo. Most nHDL-[³H]FC and [¹⁴C]PL are rapidly extracted by the liver via SR-B1 (scavenger receptor class B member 1) and spontaneous transfer; hepatic PL uptake is promoted by PL transfer protein. nHDL-[¹²⁵I]apo AI transfers to HDL and to the lipid-free form that can be recycled to nHDL formation. Cholesterol esterification by lecithin:cholesterol acyltransferase is a minor process in nHDL metabolism. These findings could guide the design of therapies that better mobilize peripheral tissue-FC to hepatic disposal.

Impact of site-specific N-glycosylation on cellular secretion, activity and specific activity of the plasma phospholipid transfer protein

The plasma phospholipid transfer protein (PLTP) plays a key role in lipid and lipoprotein metabolism. It has six potential N-glycosylation sites. To study the impact of these sites on PLTP secretion and activity, six variants containing serine to alanine point mutations were prepared by site-directed mutagenesis and expressed in Chinese hamster ovary Flp-In cells. The apparent size of each of the six PLTP mutants was slightly less than that of wild type by Western blot, indicating that all six sites are glycosylated or utilized. The size of the carbohydrate at each N-glycosylation site ranged from 3.14 to 4.2kDa. The effect of site-specific N-glycosylation removal on PLTP secretion varied from a modest enhancement (15% and 60%), or essentially no effect, to a reduction in secretion (8%, 14% and 32%). Removal of N-glycosylation at any one of the six glycosylation sites resulted in a significant 35-78% decrease in PLTP activity, and a significant 29-80% decrease in PLTP specific activity compared to wild type. These data indicate that although no single N-linked carbohydrate chain is a requirement for secretion or activity, the removal of the carbohydrate chains had a quantitative impact on cellular secretion of PLTP and its phospholipid transfer activity.

N-Glycosylation is Required for Secretion-Competent Human Plasma Phospholipid Transfer Protein

Human plasma phospholipid transfer protein (PLTP) contains six potential N-glycosylation sites (Asn-X-Ser). To study the role of these sites on PLTP structure and function, seven variants in which asparagine (N) residues were converted to glycine (G) were prepared by site-directed mutagenesis. These were N(47)G, N(77)G, N(100)G, N(126)G, N(228)G, N(381)G and N(47, 77, 100, 126, 228, 381)G (N(null)G). These variants and wild-type (WT) PLTP were expressed in COS-7 cells. Intracellular and secreted PLTP mass was analyzed by Western blots and quantitative enzyme-linked immunosorbent assay; PLTP activities in cellular lysates and media were based on the transfer of [(3)H]dipalmitoylphosphatidylcholine from phospholipid single bilayer vesicles to HDL. N(null)G was not detected intracellularly. N(381)G was similar to WT PLTP with respect to specific activity and secretion efficiency. The specific activities of N(47)G, N(77)G, N(100)G, N(126)G, N(228)G and N(381)G were similar in cell lysate (range = 67-90% WT) and medium (range = 65-77% WT). Intracellular masses of these PLTP variants were similar to that of WT (Mean = 103% WT); mean secreted mass was 88% WT. These results suggest that secretion-competent PLTP requires glycosylation but that no single glycosylation site is required.

Phospholipid transfer protein can transform reconstituted discoidal HDL into vesicular structures

The present study investigated the effect of phospholipid transfer protein (PLTP) on transformation of discoidal HDL (d-HDL) to vesicular structures by using primarily KBr density gradient centrifugation, non-denaturing gradient gel electrophoresis, and electron microscopy. The incubation of reconstituted d-HDL preparations containing apo-AI with PLTP resulted in the formation of vesicular structures differing in hydrated densities and sizes. The extents of transformation were dependent upon PLTP concentrations and incubation times. Substantial transformations occurred, even with plasma concentrations of PLTP, within 4 h of incubation at 37 degrees C. After 8 h of incubation, almost 80% of d-HDL was converted to vesicular structures with a hydrated density of 1.07 g ml-1. The d-HDL-vesicle transformation appeared to be triggered by the PLTP-mediated displacement of apo-AI. This apo-AI displacement might have led to the fusion of transiently produced apo-AI deficient particles, producing thermodynamically stable vesicular structures. The cross-linking of apo-AI in d-HDL almost completely prevented d-HDL-vesicle transformation. The addition of free apo-AI to the PLTP/d-HDL incubation mixtures also greatly reduced the transformation. The conversion of smaller vesicles of density 1.07 g ml-1 to larger vesicles of density 1.05 g ml-1 also seemed to have been affected by PLTP-mediated apo-AI displacement. We described the possible implications of the transformation of d-HDL into vesicular structures in lipid and lipoprotein transport processes under physiological and pathological conditions.

Phospholipid transfer protein mediates transfer of not only phosphatidylcholine but also cholesterol from phosphatidylcholine-cholesterol vesicles to high density lipoproteins

Phospholipid transfer protein (PLTP) purified from human plasma was found to enhance the transfer of cholesterol from single bilayer vesicles containing phosphatidylcholine and cholesterol to high density lipoprotein-3. The rate of cholesterol transfer was greatly influenced by the cholesterol content of the donor vesicles. The maximal rate was observed with the vesicles containing 20-25 mol % cholesterol. This was in contrast to a progressive decline in the rate of phosphatidylcholine transfer with an increase in the cholesterol content. To determine the binding of cholesterol and phosphatidylcholine to PLTP, the mixtures of PLTP and the vesicles containing 3H-labeled phosphatidylcholine and 14C-labeled cholesterol were incubated and subjected to sucrose density gradient centrifugation. Determination of the label profiles showed that cholesterol as well as phosphatidylcholine were transferred from the vesicles to PLTP. The reversible nature of the binding was shown by the transfer of labeled cholesterol and phosphatidylcholine bound to PLTP to the acceptor vesicles or low density lipoprotein. Isothermal equilibrium binding of PLTP for cholesterol and phosphatidylcholine showed that PLTP possessed a considerably higher affinity and binding capacity for phosphatidylcholine than for cholesterol. The phosphatidylcholine binding affinity and capacity were greater when PLTP was incubated with phosphatidylcholine vesicles without cholesterol. A possible importance of PLTP-mediated cholesterol transfer in the circulation was described.

Plasma factors affecting the in vitro conversion of high-density lipoproteins labeled with a non-transferable marker

We studied the in vitro conversion of HDL3 labeled with a radioiodinated diacyl lipid associating peptide (diLAP). DiLAP was previously shown to be nontransferable, which permitted its' use as a reliable marker of HDL particles. DiLAP-labeled HDL3 was incubated for 23 h at 37 degrees C in human or rat plasma or in reconstituted media containing delipidated plasma and/or lipoproteins and/or partially purified CETP. At the end of the incubations, the samples were adjusted to a density of 1.125 g/ml and ultracentrifuged. The two resulting fractions containing HDL2 and HDL3, respectively, were analyzed by gradient gel electrophoresis. Depending upon experimental conditions, diLAP-labeled HDL3 was converted into HDL2b- and/or small HDL3c-like particles. LCAT inhibition and to a lesser extent CETP promoted the formation of small HDL3c. Reactivation of LCAT led to the disappearance of small HDL3c. No HDL3c formed from HDL2 even in the absence of LCAT activity. When the incubations were performed in the presence of 100 mM thimerosal, which inhibited PLTP but not CETP activity, the conversion of diLAP-labeled HDL3 into HDL2 was almost completely blocked. Collective consideration of these data indicates that the formation of small HDL is moderately facilitated by CETP; that small HDL are converted to larger HDL species by LCAT and that the transformation of HDL3 into HDL2 is a process which largely depends upon PLTP activity.

Cholesteryl ester analogs inhibit cholesteryl ester but not triglyceride transfer catalyzed by the plasma cholesteryl ester-triglyceride transfer protein

A lipid transfer protein complex (LTC), purified from human plasma by immunoaffinity chromatography, catalyzed the interlipoprotein transfer of cholesteryl esters (CE) and triglycerides (TG). The CE transfer activity of LTC was governed by the structure of the CE. Incubation of LTC with long chain CE both activated and stabilized LTC. Short chain CE also enhanced the CE and TG transfer activity of LTC during the initial time of incubation. However, LTC's incubation with short chain CE induced a subsequent and time-dependent loss of CE transfer activity without concomitant loss of TG transfer activity. The data indicate that the CE and TG transfer activity of LTC can be regulated independently.

Phospholipid transfer proteins: mechanism of action

Phospholipid transfer proteins are generally localized in the cytosolic fraction of cells and are capable of catalyzing the flux of phospholipid molecules among membranes. Artificial membranes also participate in protein-catalyzed phospholipid movements. In this review the major phospholipid transfer proteins are discussed with respect to their phospholipid substrate specificity and the contributions of membrane physical properties to this process. The phenomenon of net transfer of phospholipids is described. The use of various kinetic approaches to the study of these catalysts is reviewed. A detailed consideration of the distinct phospholipid binding and membrane interaction domains of one phospholipid transfer protein is presented. Finally, some recent applications of phospholipid transfer proteins to the examination of membrane structure and function and further directions for the continued research activity with this class of proteins are summarized.

Immunoaffinity purification of the lipid transfer protein complex directly from human plasma

The human cholesteryl ester (CE) and triglyceride (TG) exchange protein (denoted LTC or lipid transfer complex) was isolated in a single step from plasma using immunoaffinity batch extraction. Antibodies were raised against two preparations of conventionally purified LTC. LTC-I and LTC-II (purified 20,000-fold and 3500-fold, respectively) were used as immunogens. The antiLTC antibodies were isolated by anion-exchange chromatography and coupled to Affi-Gel 10. Chromatography of plasma on antiLTC Affi-Gel removed all of the CE and TG transfer activity. Moreover, LTC prepared from both antiLTC-I and antiLTC-II-Affi-Gel matrices were identical when analyzed by sodium dodecyl sulfate-polyacrylamide gel LTC electrophoresis. LTC exhibited two protein bands of Mr (apparent) 67,000 and 58,000 and a broad, faintly staining region at greater than 150,000. Analysis of LTC by immunoblotting indicated that both antiLTC-I and antiLTC-II antibodies recognized the same LTC proteins. Isoelectric focussing of LTC gave two pI values, 5.2 and 8.7. These data suggest that LTC is a complex of specific proteins and perhaps lipid. Specific CE and TG exchange activities of immunoaffinity-purified LTC were comparable, although the activities were low with respect to that of the antigen used to generate antiLTC-I. This is not due to contamination of LTC by albumin, lecithin:cholesterol acyltransferase, or apolipoproteins AI, AII, B, CIII, D, or E.

Spontaneous and plasma factor-mediated transfer of pyrenyl cerebrosides between model and native lipoproteins

A series of pyrenyl glucocerebrosides was synthesized by reacylation of psychosine with pyrene-labeled fatty acids having 3-11 methylene units. When incorporated into model high-density lipoproteins consisting of dimyristoylphosphatidylcholine-apolipoprotein A-II complexes and incubated with unlabeled complexes, these lipids exhibited spontaneous transfer. Half times of transfer varied from 1.5 min to 365 min at 37 degrees C. The logarithm of the rate of transfer was linearly related to the number of fatty acyl methylene units and HPLC retention time. Transfer occurred by passage of lipid monomers through the aqueous phase. Spontaneous transfer of the glycolipids also occurred when they were incorporated into native high-density lipoproteins. Rates of transfer between native high-density lipoprotein particles were higher than those observed between model high-density lipoprotein particles. A partially purified lipid exchange protein from plasma, as well as unfractionated lipoprotein-deficient serum, stimulated the transfer of fluorescent glycolipid between model high-density lipoprotein or native high-density lipoprotein and low-density lipoprotein 2-24 fold. The protein also stimulated the transfer of tritiated ganglioside GM3 between native low-density lipoprotein and high-density lipoprotein. This protein may play a role in glycolipid exchange in vivo.

Purification and characterization of a phosphatidylinositol transfer protein from human platelets

We report the purification of a phospholipid transfer protein from human platelets. This protein preferentially transfers phosphatidylinositol, with phosphatidylcholine and phosphatidylglycerol being transferred to a lesser extent. Phosphatidylethanolamine is not transferred. Transfer activity is detected by measuring the transfer of radiolabeled phospholipids between two populations of small unilamellar vesicles. The protein was purified approximately 1000-fold over the platelet cytosol by chromatography on Sephadex G-75, sulfooxyethyl cellulose, and hydroxylapatite. The molecular weight of this protein appears to be 28 000 as determined by gel filtration chromatography. When the purified protein is analyzed on sodium dodecyl sulfate-polyacrylamide gels, two major components and several minor ones are observed. The molecular weight of the two major bands are 28 600 and 29 200. Isoelectric focusing of the platelet cytosol yielded phosphatidylinositol and phosphatidylcholine transfer activity at pH 5.6 and 5.9. The platelet phospholipid transfer protein is able to catalyze the transfer of phosphatidylinositol and phosphatidylcholine between vesicles and human platelet plasma membranes. One possible physiological role for this transfer protein is an involvement in the rapid turnover of inositol-containing lipids which occurs upon exposure of platelets to various stimuli.

Equilibrium of apoproteins between high density lipoprotein and the aqueous phase: modelling of in vivo metabolism

There is a growing body of evidence that apoproteins of the high density lipoproteins (HDL) exchange between lipoprotein particles through the aqueous phase and that there is always a finite but physiologically important quantity of lipid-free apoprotein in plasma. We have studied the theoretical consequences of this concept on the catabolism of apoproteins and developed a testable model for studying the in vivo metabolism of HDL apoproteins. This model describes the putative modification of the apparent tissue distribution spaces of the apoprotein that would result from a change in the partitioning of this apoprotein between HDL and the aqueous phase. The main parameters predicted by the model include the tissue distribution spaces of free monomeric apoprotein, those of HDL-bound apoprotein and the partition coefficient of the apoprotein between HDL and the aqueous phase in blood. We have designed several ways of testing this model in vivo including the use of model synthetic apoproteins. This model can be generalized to a number of other binding systems.

Lipoproteins and lipoprotein metabolism. A dynamic evaluation of the plasma fat transport system

Data now available suggest that a dynamic equilibrium exists in the plasma lipoproteins. Chylomicrons and very low density lipoproteins (VLDL) are primary secretory products of cells and carry triglycerides through the blood stream. As intravascular triglyceride hydrolysis occurs via the action of lipoprotein lipase (LPL), the further metabolism of nontriglyceride constituents of chylomicrons and VLDL can be followed along two interrelated pathways. Along the core pathway, cholesterol ester increasingly becomes a major core lipid with resultant formation of intermediate density (IDL, or remnant particles) and eventually low density (LDL) lipoprotein. Concomitant with reduction of core volume, redundant surface lipids and proteins move along a surface pathway and either form high density (HDL) lipoprotein precursors, or become associated with existing HDL particles. Cholesterol esters are formed via the action of lecithin: cholesterol acyltransferase (LCAT) in HDL. Therefore, action of LPL and LCAT on triglyceride-rich lipoproteins and their catabolic products is sufficient and necessary for formation, in plasma, of LDL and HDL. Once formed, all plasma lipoproteins are further remodelled by the activity of exchange and transfer reactions. In humans, a major remodelling occurs through exchange of LDL and HDL cholesterol ester by VLDL (and chylomicrons) triglyceride. The reaction is the main source of cholesterol esters in triglyceride-rich lipoproteins and is responsible for the enrichment of LDL and HDL with triglycerides. When followed by triglyceride lipolysis, this cycle results in limitation of size and cholesterol content of both LDL and HDL. The physiology and pathophysiology of the plasma lipid transport system in humans can therefore be fully appreciated only when the interrelations of all these metabolic reactions is taken into account.

Transfer of [14C]phosphatidylcholine between liposomes and human plasma high density lipoprotein. Partial purification of a transfer-stimulating plasma factor using a rapid transfer assay

A simple method was developed for the rapid determination of [14C]phosphatidylcholine transfer from small unilamellar liposomes to human plasma HDL, based on the selective precipitation of liposomes by heparin and MnCl2. The assay was utilized to monitor the progress in the partial purification of a phospholipid transfer factor from human plasma. The purification procedure included ultracentrifugation at d = 1.25 g/ml, hydrophobic chromatography on phenyl-Sepharose, affinity chromatography on heparin-Sepharose and gel filtration. The partially purified protein(s) catalyzed the net transfer of phospholipid from small unilamellar phosphatidylcholine liposomes to isolated HDL. The transfer of [14C]phosphatidylcholine from liposomes consisting of phosphatidylcholine/phosphatidylserine/cholesterol (molar ratio, 4:1:5) to HDL was stimulated without affecting the permeability barrier of the liposomal membranes and is, therefore, taken to represent exchange with HDL phospholipid rather than net transfer.

Kinetics of spontaneous and plasma-stimulated sphingomyelin transfer

The mechanism of transfer of a pyrene-labeled sphingomyelin (PySM) between different lipid compartments was studied by a fluorescence technique. The first-order kinetics are independent of donor and acceptor concentration and the identity of the acceptor; the rates are accelerated by 'structure-breaking' solutes and inhibited by 'structure-making' solutes. These observations are consistent with the transfer of PySM occurring via the aqueous phase that separates the donor and acceptor compartments. We have partially purified a plasma factor that stimulates the transfer rate. Our in vitro results suggest that both spontaneous and stimulated transfer might contribute to the redistribution of sphingomyelin in vivo,

An in vitro ESR study of uncatalyzed rat liver protein-catalyzed spin-labeled phosphatidylcholine exchange

ESR spectrometry has been used to study fatty acid spin-labeled phosphatidylcholine exchange from single bilayer donor vesicles to various acceptor systems, such as intact or differently treated mitochondria, phospholipid multilamellar vesicles or single bilayer vesicles. This exchange is catalyzed by soluble non-specific rat liver protein, first investigated by Bloj and Zilversmit in 1977 (J. Biol. Chem. 252, 1613--1619). Non-catalyzed phosphatidylcholine exchange has also been studied. Full inhibition of both mechanisms occurs with lipid-depleted acceptor mitochondria, while N-ethylmaleimide-treated mitochondria behave as good acceptors during catalyzed exchange but are in no way effective during spontaneous exchange. Non-catalyzed exchange does not take place with phospholipase D-treated mitochondria as acceptors, while the pure catalyzed mechanism is inhibited by 28%. Neither multilamellar nor single bilayer phospholipid vesicles exchange spin-labeled phosphatidylcholine in the absence of protein, the former being a poorer acceptor system than the latter during catalyzed exchange, when this activity is 31 and 80%, respectively, of that of intact mitochondria. The hypothesis is made that the spontaneous mechanism is active among intact natural membranes and could be of some importance in vivo. Furthermore, the biomembrane protein moiety is assumed to be involved in the catalyzed exchange more as a phospholipid spacer than as a binder between the exchange protein and the membrane involved. Phospholipids, on the contrary, appear to be important for both functions.

Phosphatidylinositol turnover in mitogen-activated lymphocytes. Suppression by low-density lipoproteins

Low-density (LD) lipoproteins inhibit phytohaemagglutinin-enhanced turnover of phosphatidylinositol in human peripheral lymphocytes. Turnover was assessed by (32)P incorporation into phospholipids and by loss of (32)P from [(32)P]phosphatidylinositol. Inhibition of lipid turnover by LD lipoproteins is not the result of a change in the amount of phytohaemagglutinin required for maximum cellular response. Neither phytohaemagglutinin nor LD lipoproteins influence (32)P incorporation into phosphatidylethanolamine and phosphatidylcholine during the first 60min after mitogenic challenge. The extent of inhibition of phosphatidylinositol turnover by LD lipoproteins depends on the concentration of LD lipoproteins present in the incubation medium: 50% of maximum inhibition occurs at a low-density-lipoprotein protein concentration of 33mug/ml and maximum inhibition occurs at low-density-lipoprotein protein concentrations above 100mug/ml. Phytohaemagglutinin stimulates (32)P incorporation into phosphatidylinositol, phosphatidylinositol phosphate and phosphatidylinositol bisphosphate. However, LD lipoproteins abolish (32)P incorporation into phosphatidylinositol without affecting incorporation into phosphatidylinositol phosphate and phosphatidylinositol bisphosphate. The ability of LD lipoproteins to inhibit phytohaemagglutinin-induced phosphatidylinositol turnover is mimicked by EGTA. Furthermore, inhibition of LD lipoproteins by phytohaemagglutinin-induced (32)P incorporation into phosphatidylinositol correlates directly with inhibition by LD lipoproteins of Ca(2+) accumulation. These results suggest that Ca(2+) accumulation and turnover of phosphatidylinositol are coupled responses in lymphocytes challenged by mitogens. The step in phosphatidylinositol metabolism that is sensitive to LD lipoproteins and, by inference, that is coupled to Ca(2+) accumulation is release of [(32)P]phosphoinositol from phosphatidylinositol.

Effect of lipoprotein-free plasma on the interaction of human plasma high density lipoprotein with egg yolk phosphatidylcholine liposomes

Liposomes consisting of 14C-labeled egg yolk phosphatidylcholine were incubated with whole human plasma or plasma subfractions. The transfer of liposomal phospholipid to plasma high density lipoprotein was determined by gel filtration. Whole plasma degraded the liposomes considerably faster than isolated high density lipoprotein. The phospholipid-transferring activity of whole plasma could be recovered in an equivalent mixture of isolated high density lipoprotein and lipoprotein-free plasma. The transfer stimulating activity in lipoprotein-free plasma was not associated with albumin but with a component of higher molecular weight. Upon incubation of lipoprotein-free plasma with liposomes this component appeared to be adsorbed to the liposomes and could thus be separated from the bulk protein by gel filtration. This binding to liposomes is taken as an indication that the component acts by modifying the lipid-water interface thus facilitating the insertion of the lipoprotein into the liposomal bilayer.

Lipoprotein synthesis and secretion by cultured human intestinal mucosa

We tested whether cultured human jejunal mucosa incorporates fatty acid into esterified lipids and whether organ culture can serve as a model system to study lipoprotein secretion by the human gut. Jejunal biopsies obtained from seven subjects were cultured for 24 h in medium containing 2 microCi of [3H]palmitic acid. More than 95% of the radioactivity incorporated by the tissue was found to be associated with esterified lipids: triglycerides, cholesterol esters and phospholipids, 7 . 8 +/- 1 . 2, 0 . 5 +/- 0 . 1 and 14 . 0 +/- 1 . 5 nmol/10 mg weight respectively. During the culture labelled triglycerides, phospholipids and cholesterol esters were secreted to the medium. Most of the newly synthesized esterified lipids in the medium were found in the d < 1 . 019 g/ml and d = 1 . 019--1 . 063 g/ml fractions. The majority of the newly synthesized triglycerides were found in the d < 1 . 019 g/ml fraction. Labelled cholesterol esters were enriched in the d = 1 . 063--1 . 21 g/ml fraction. Boiled biopsies adsorbed negligible amounts of radioactive palmitic acid and did not synthesize esterified lipids. The addition of puromycin to the culture medium and preincubation with colchicine resulted in decreased uptake of the labelled fatty acid and decreased secretion of esterified lipids to the medium. These experiments indicate that cultured human intestinal mucosa is a suitable model to study lipid synthesis and lipoprotein secretion by the human intestine.

Asymmetry in the renewal of molecular classes of phosphatidylcholine in the rat-erythrocyte membrane

1. Rat-blood phospholipids were labeled in vivo with [32P]phosphate. The erythrocytes were treated with phospholipase A2 plus sphingomyelinase to discriminate between the labeling patterns of the phospholipids from the inner and outer layer of the membrane. 2. The specific activities of the more unsaturated classes of phosphatidylcholine were higher in the outer layer of the erythrocyte membrane than in the inner layer. The disaturated class, however, had the highest specific activity in the inner layer. 3. After incubating 32P-labeled erythrocytes in unlabeled plasma, the labeling pattern recovered in the molecular classes of plasma phosphatidylcholine was very similar to that of the phosphatidylcholines in the outer layer of the erythrocyte membrane. 4. It is proposed that the exchange of phosphatidylcholines between plasma and the outer layer of the erythrocyte is mainly responsible for the renewal of the unsaturated phosphatidylcholines of the erythrocyte, and that the acylation activity of the erythrocyte is directed towards the formation of disaturated phosphatidylcholines at the inside of the membrane.

Atherogenesis: a postprandial phenomenon

The hypothesis that plasma chylomicrons in persons who ingest a cholesterol-rich diet are atherogenic is evaluated. Evidence is presented that in humans, and experimental animals, chylomicron remnants as well as low-density lipoproteins are taken up by arterial cells. In persons who do not have familial hyperlipoproteinemia, atherogenesis may occur during the postprandial period. Research directions that may contribute to the evaluation of chylomicron remnants as a risk factor for atherogenesis are discussed. Lipoprotein studies after administration of a test meal containing fat and cholesterol are urgently needed.